Nevada § 29.5 - Duties of Joint Interim Standing Committee on Health and Human Services; report; definitions

§ 29.5. Duties of Joint Interim Standing Committee on Health and Human Services; report; definitions

1. During the 2023-2024 interim, the Joint Interim Standing Committee on Health and

Human Services, in coordination with the Department of Health and Human Services,

shall study the cost-effectiveness of biomarker testing, including, without limitation,

the cost-effectiveness of biomarker testing: (a) For the diagnosis, treatment, management or ongoing monitoring of specific diseases

or conditions; and (b) To screen for specific diseases or conditions or traits associated with specific

diseases or conditions. 2. The Joint Interim Standing Committee on Health and Human Services shall submit

a report of the results of the study, including any recommendations for legislation

to the Director of the Legislative Counsel Bureau for transmission to the 83rd Session

of the Nevada Legislature. 3. As used in this section: (a) “ Biomarker ” means a characteristic that is objectively measured and evaluated as an indicator

of a normal biological process, a pathogenic process or a pharmacological response

to a specific therapeutic intervention and includes, without limitation: (1) An interaction between a gene and a drug that is being used by or considered for

use by the patient; (2) A mutation or characteristic of a gene; and (3) The expression of a protein. (b) “ Biomarker testing ” means the analysis of the tissue, blood or other biospecimen of a patient for the

presentation of a biomarker and includes, without limitation, single-analyte tests,

multiplex panel tests and whole genome, whole exome and whole transcriptome sequencing.